ArticleWorld journal of surgical oncology2026
Predicting microvascular invasion in hepatocellular carcinoma using US features combined with clinicopathological characteristics: a multicenter study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo enhance the clinical management of hepatocellular carcinoma (HCC), we explored how conventional ultrasound and pathological features vary with microvascular invasion (MVI) status. We identified key risk factors for MVI and developed a straightforward preoperative model to predict MVI status.
methodsIn this study, we enrolled 362 patients with HCC confirmed by surgical pathology from three medical institutions, collecting their clinical pathological and ultrasound features. Patients from institutions 1 and 2 were randomly split into training and internal validation sets at a 7:3 ratio, while those from institution 3 served as the external validation set. We used least absolute shrinkage and selection operator (LASSO) and best subset regression (BSR) to select variables for model building. A nomogram was constructed to predict hepatocellular carcinoma MVI, and its accuracy, clinical utility, and discrimination were assessed using ROC, clinical decision curves, and calibration plots.
resultsA total of 175 patients were included in the study. Of these, 135 patients from institutions 1 and 2 were randomly divided into a training set (95 patients) and an internal validation set (40 patients). Among them, 57.0% (77/135) were MVI-negative, and 43.0% (58/135) were MVI-positive. Only total cholesterol (TC) levels were significantly higher in the MVI-positive group (p<0.05). No other laboratory or conventional ultrasound features showed significant differences between the two groups. Using BSR and LASSO regression analyses, we identified four independent risk factors for MVI from conventional ultrasound features: margin, shape, echogenicity, and relationship to the capsule. A nomogram was created based on these four features. The area under the receiver operating characteristic curve (AUC) for the MVI prediction model was 0.881 (95% CI: 0.815–0.948) in the training set, 0.790 (95% CI: 0.644–0.936) in the internal validation set, and 0.823 (95% CI: 0.692–0.953) in the external validation set.
conclusionsConventional ultrasound features can accurately predict MVI in HCC. A predictive model based on these features offers a simple and effective tool for assessing the invasiveness of liver cancer in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.